Zacks Investment Research Downgrades Kura Oncology (NASDAQ:KURA) to Hold

Zacks Investment Research lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Other equities analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $29.00 price target on shares of Kura Oncology in a research note on Friday, August 2nd. Leerink Swann set a $27.00 target price on Kura Oncology and gave the company a buy rating in a research note on Saturday, June 15th. ValuEngine upgraded Kura Oncology from a buy rating to a strong-buy rating in a research report on Monday, June 17th. Deutsche Bank began coverage on Kura Oncology in a research report on Thursday, July 18th. They set a buy rating and a $28.00 price target on the stock. Finally, Citigroup lifted their price target on Kura Oncology from $18.00 to $25.00 and gave the company a buy rating in a research report on Friday, May 24th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average price target of $27.89.

Shares of NASDAQ KURA opened at $15.81 on Wednesday. The stock has a 50-day moving average price of $19.12 and a two-hundred day moving average price of $16.93. The company has a market cap of $768.65 million, a price-to-earnings ratio of -9.19 and a beta of 2.51. Kura Oncology has a 12 month low of $10.20 and a 12 month high of $21.42. The company has a current ratio of 23.50, a quick ratio of 23.50 and a debt-to-equity ratio of 0.03.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 1st. The company reported ($0.38) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.03. On average, sell-side analysts predict that Kura Oncology will post -1.61 earnings per share for the current year.

In related news, insider Antonio Gualberto sold 18,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total value of $379,980.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 11.00% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its holdings in Kura Oncology by 21.7% in the fourth quarter. Legal & General Group Plc now owns 5,175 shares of the company’s stock valued at $73,000 after buying an additional 923 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Kura Oncology by 164.9% during the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock worth $38,000 after purchasing an additional 1,204 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Kura Oncology during the second quarter worth about $25,000. Wells Fargo & Company MN grew its holdings in shares of Kura Oncology by 3.3% during the second quarter. Wells Fargo & Company MN now owns 42,448 shares of the company’s stock worth $835,000 after purchasing an additional 1,346 shares during the last quarter. Finally, CWM LLC purchased a new position in shares of Kura Oncology during the first quarter worth about $25,000. 79.65% of the stock is currently owned by hedge funds and other institutional investors.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Further Reading: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.